

RNS Number : 9573Y  
EKF Diagnostics Holdings PLC  
14 September 2020

**EKF Diagnostics Holdings plc**  
**("EKF", the "Company" or the "Group")**

**Dividend Timetable Amendment**

Further to the interim results announcement released this morning, the dividend timetable should be amended to refer to the following key dates:

Ex-dividend date: 5 November 2020  
Record date: 6 November 2020  
Payment date: 1 December 2020

**EKF Diagnostics Holdings plc**  
Christopher Mills, Non-executive Chairman  
Julian Baines, CEO  
Richard Evans, FD & COO

[www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)  
**Tel: +44 (0) 29 2071 0570**

**N+1 Singer**  
Aubrey Powell / George Tzimas (Corporate Finance)  
Tom Salvesen (Corporate Broking)

**Tel: 020 7496 3000**

**Walbrook PR Limited**  
Paul McManus / Lianne Cawthorne

**Tel: +44 (0) 20 7933 8780 or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)**  
Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303

**About EKF Diagnostics Holdings plc ([www.ekfdiagnostics.com](http://www.ekfdiagnostics.com))**

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock

Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

FURGPUMUBUPUGMC admin Dividend Timetable Amendment 31173305 A Mon, 09/14/2020 - 18:14 LSE RNS Company Announcement - General EKF